Elevated serum levels of miR-19a-3p in patients with metastatic HER2 + breast cancer treated with trastuzumab may serve as a tumor biomarker for identifying those with effective immune responses who are likely to benefit from anti-HER2 therapy. This evidence concerns the gene ERBB2 and breast carcinoma.